Physician profile
Howard B Kushner
NPI 1366550410
$1,271.92
in general payments reported to CMS, 2019-2025
9 companies · $535 in 2025
The $535 reported for 2025 was more than what 85% of Vision Therapy providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $42.95 · 2024: $694 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,271.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $588.37 | 2024-2025 | Miebo, Vyzulta, Xiidra |
| Astellas Pharma US INC | $154.64 | 2024-2025 | Izervay |
| Tarsus Pharmaceuticals, INC. | $136.94 | 2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $108.80 | 2024 | Syfovre |
| Mallinckrodt Hospital Products INC. | $99.80 | 2024 | Acthar |
| Alcon Vision LLC | $68.15 | 2024-2025 | Precision7, Rocklatan |
| Abbvie INC. | $51.27 | 2024-2025 | |
| Rxsight INC | $42.95 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Genentech USA, INC. | $21.00 | 2025 | Vabysmo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Kushner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.